

Canine CXCL13 / BCA-1 Protein (His Tag)

Catalog Number: 70057-D07E



Sino Biological Inc.

Biological Solution Specialist

General Information

Gene Name Synonym:

CXCL13

Protein Construction:

A DNA sequence encoding the canine CXCL13 (XP_851619.3) (Val23-Asn110) was expressed with a N-terminal polyhistidine tag.

Source: Canine

Expression Host: E. coli

QC Testing

Purity: > 95 % as determined by SDS-PAGE

Endotoxin:

Please contact us for more information.

Stability:

Samples are stable for up to twelve months from date of receipt at -70 °C

Predicted N terminal: His

Molecular Mass:

The recombinant canine CXCL13 comprises 104 amino acids and has a predicted molecular mass of 12.1 kDa. The apparent molecular mass of the protein is approximately 15 kDa in SDS-PAGE under reducing conditions due to glycosylation.

Formulation:

Lyophilized from sterile PBS, pH 7.4.

Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.


Usage Guide

Storage:

Store it under sterile conditions at -20°C to -80°C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

SDS-PAGE:



Reconstitution:

Detailed reconstitution instructions are sent along with the products.

Protein Description

CXCL13, also known as BCA-1 (B-cell-attracting chemokine-1) or BLC (B-lymphocyte chemoattractant), is a major regulator of B-cell trafficking. CXCL13 is a small cytokine belonging to the CXC chemokine family. CXCL13 and its receptor CXCR5 control the organization of B cells within follicles of lymphoid tissues. CXCL13 is known to dictate homing and motility of B cells in lymphoid tissue and has been implicated in the formation of ectopic lymphoid tissue in chronic inflammation. The increased level of CXCL13 is a feature of systemic lupus erythematosus (SLE) that correlates with disease activity. Furthermore, CXCL13 might be a readily available surrogate marker to monitor the extent of aberrant B-cell (dys-)function. The vascular endothelial BCA-1 expression may be consequent to transcytosis. In Primary central nervous system lymphoma (PCNSL), expression of BCA-1 by malignant lymphocytes and vascular endothelium may influence tumor development and localization to central nervous system (CNS). CXCL13 expression is a distinctive feature of angioimmunoblastic T-cell lymphoma, providing further support for the germinal center T-helper cell as the cell of origin for this neoplasm. Furthermore, CXCL13, a chemokine that may participate in tumor pathogenesis and is a potential target for novel therapies.

References

1. Ansel KM. et al., 2000, Nature. 406 (6793): 309-14.
2. Schiffer L. et al., 2009, Nephrol Dial Transplant. 24 (12): 3708-12.
3. Rupprecht TA. et al., 2009, J Neuroinflammation. 6: 42.
4. Smith JR. et al., 2003, Blood. 101 (3): 815-21.
5. Grogg KL. et al., 2006, Mod Pathol. 19 (8): 1101-7.
6. Falkenhagen KM. et al., 2005, Am J Ophthalmol. 140 (2): 335-7.

Manufactured By Sino Biological Inc., FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Fax :+86-10-51029969 • Tel:+86-400-890-9989 • <http://www.sinobiological.com>